SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin planning to launch around 30 generic products in US market

25 Jun 2018 Evaluate

Lupin is planning to launch around 30 generic products in the US market this year. The company has currently 162 abbreviated new drug applications pending approval with the US Food and Drug Administration (USFDA).

The company is banking on introduction of complex generics and biosimilars in the US, besides continuing focus on exclusive and semi-exclusive products in oral and injectable space to maintain its top five position in the market.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2512.80 22.95 (0.92%)
08-Jul-2026 10:15 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1908.60
Dr. Reddys Labs. 1366.00
Cipla 1454.65
Zydus Lifesciences 1170.85
Lupin 2512.80
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: